ImmunoGen Announces Webcast of Presentation at the Piper Jaffray 31st Annual Healthcare Conference
WALTHAM, Mass.--(BUSINESS WIRE)--Nov 26, 2019--
ImmunoGen, Inc., (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will participate in a fireside chat at the upcoming Piper Jaffray Healthcare Conference. The fireside chat is scheduled for 12:30 p.m. ET on December 3, 2019.
A webcast of the fireside chat will be accessible live through the “Investors & Media” section of the Company’s website, www.immunogen.com; a replay will be available in the same location for approximately two weeks.
ImmunoGen is developing the next generation of antibody-drug conjugates to improve outcomes for cancer patients. By generating targeted therapies with enhanced anti-tumor activity and favorable tolerability profiles, we aim to disrupt the progression of cancer and offer our patients more good days. We call this our commitment to “target a better now.”
Learn more about who we are, what we do, and how we do it at www.immunogen.com.
View source version on businesswire.com:https://www.businesswire.com/news/home/20191126005127/en/
CONTACT: INVESTOR RELATIONS AND MEDIA
KEYWORD: MASSACHUSETTS UNITED STATES NORTH AMERICA
INDUSTRY KEYWORD: BIOTECHNOLOGY PHARMACEUTICAL HEALTH ONCOLOGY
SOURCE: ImmunoGen, Inc.
Copyright Business Wire 2019.
PUB: 11/26/2019 04:30 PM/DISC: 11/26/2019 04:30 PM